Treatment of hepatitis C in renal transplantation candidates: A single-center experience

T. Werner, Bashar Aqel, Vijayan Balan, Thomas Byrne, Elizabeth Carey, David Douglas, Raymond L. Heilman, Jorge Rakela, Kristin Mekeel, Kunam Reddy, Hugo E. Vargas

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background. There is no consensus on hepatitis C virus (HCV) treatment in patients with renal failure. Toxicity of pegylated interferon (PEG-IFN) and ribavirin limit options; hence the ideal approach for therapy in these patients deserves attention. We report the results of kidney transplantation (KTx) candidates infected with HCV treated with PEG-IFN monotherapy. Methods. KTx candidates with HCV infection treated with PEG-IFN monotherapy between January 2001 and February 2009 were included. Liver biopsies were performed before therapy. Response was assessed using accepted virological time points. Results. From 2636 patients listed for KTx, 60 patients were tested positive for anti-HCV. Twenty-two patients were eligible for treatment. All patients were HCV treatment naïve. One patient had biopsy-confirmed cirrhosis. Mean Ishak-Knodell fibrosis stage was 1.3. Ten patients (45%) achieved sustained viral response. In genotype 1 patients, there were no relapsers among early responders, despite the limited regimen. Nine patients (40%) in the cohort have had KTx. Of these, there were four responders and five nonresponders. None of the responders have had recurrence of their HCV after their KTx. Conclusions. End-stage renal disease patients with HCV can be treated successfully with PEG-IFN monotherapy. Our sustained viral response rate was 45% (10/22) in patients treated before KTx.

Original languageEnglish (US)
Pages (from-to)407-411
Number of pages5
Issue number4
StatePublished - Aug 27 2010


  • End-stage renal disease
  • Hepatitis C
  • Kidney transplantation
  • Pegylated interferon monotherapy

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Treatment of hepatitis C in renal transplantation candidates: A single-center experience'. Together they form a unique fingerprint.

Cite this